Baudax Bio Stock News

Baudax Bio, Inc. (NASDAQ:BXRX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Sam Martin - Investor Relations Gerri Henwood - President and CEO Conference Call Participa

Annual Meeting to be reconvened on May 18, 2022 Annual Meeting to be reconvened on May 18, 2022

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Baudax Bio press release (BXRX): Q4 GAAP EPS of $10.03.Revenue of $0.4M (+400.0% Y/Y).CEO comment: "We are actively progressing our novel neuromuscular blocking agents, including…

Baudax Bio (NASDAQ: BXRX ) reported its Q4 earnings results on Wednesday, March 16, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Baudax Bio reported an EPS of $-4.41. Revenue was up $324.00 thousand … Full story available on Benzinga.com

ANJESO End User Demand and Revenue Increases Four Quarters In A Row

MALVERN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 2:40 p.m. Eastern Time.

Baudax Bio (BXRX) began a clinical trial evaluating the safety and pharmacokinetics ((PK)) of pain drug Anjeso (meloxicam) injection in children aged 2 to <17 years following surgery

Baudax Bio (BXRX) has regained compliance with Nasdaq''s minimum bid price requirement under Listing Rule 5550(a)(2).Nasdaq staff made this determination of compliance after the…

Baudax Bio (BXRX) has added ~3% in the pre-market Wednesday after the commercial-stage pharmaceutical company announced that the U.S

Aerie Pharmaceuticals (AERI) +25%. Schrodinger (SDGR) +17%. Baudax Bio BXRX -55%. The Joint (JYNT) -15%.

Baudax Bio BXRX -54% on pricing $10M stock and warrants offering.LivePerson LPSN -36% on Q4 earnings release.Foot Locker FL -16% on Q4 earnings release.Latch LTCH -14% on Q4…

Baudax Bio (BXRX) is down 33.8% after hours after the firm has priced its previously announced underwritten public offering of 3,508,772 shares of common stock, together with warrants…

Baudax Bio (BXRX) trades 21% down after hours on commencing a proposed underwritten public offering of shares and warrants.Underwriters to be be granted option to purchase additional…

Creative Medical Technology (CELZ) +33%. HOOKIPA Pharma (HOOK) +18%. Baudax Bio (BXRX) -11%. Nuvectis Pharma (NVCT) -11%.